GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Cash Conversion Cycle

DermTech (DermTech) Cash Conversion Cycle : 37.53 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is DermTech Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

DermTech's Days Sales Outstanding for the three months ended in Mar. 2024 was 60.29.
DermTech's Days Inventory for the three months ended in Mar. 2024 was 26.73.
DermTech's Days Payable for the three months ended in Mar. 2024 was 49.49.
Therefore, DermTech's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 37.53.


DermTech Cash Conversion Cycle Historical Data

The historical data trend for DermTech's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Cash Conversion Cycle Chart

DermTech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial - 3.70 15.28 60.51 66.74

DermTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.99 74.23 69.02 59.03 37.53

Competitive Comparison of DermTech's Cash Conversion Cycle

For the Diagnostics & Research subindustry, DermTech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DermTech's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where DermTech's Cash Conversion Cycle falls into.



DermTech Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

DermTech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=80.61+33.55-47.42
=66.74

DermTech's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=60.29+26.73-49.49
=37.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DermTech  (NAS:DMTK) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


DermTech Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of DermTech's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


DermTech (DermTech) Business Description

Traded in Other Exchanges
N/A
Address
11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
Executives
Kevin M Sun officer: Chief Financial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra officer: Chief Operating Officer C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan officer: General Counsel C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard officer: Chief Commercial Officer 19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood officer: Chief Commercial Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen director, officer: Chief Executive Officer 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak director, officer: Chief Executive Officer 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037

DermTech (DermTech) Headlines

From GuruFocus